We are pleased to report that 2002 was a year of significant progress in establishing GlaxoSmithKline as one of the world’s leading pharmaceutical companies. We achieved strong financial results in 2002, despite the entry of generic competition in the USA to Augmentin, one of our major products.

This unaudited Half-Year Review for the period ended 30th June 2002 is prepared in accordance with the accounting policies expected to apply for 2002. These are unchanged from those set out in the Annual Report 2001, except that during 2002, FRS 19 …

The case began in 2002, when GSK sent experts to fix problems cited by the FDA. The lead inspector recommended recalls of defective products, but they were not authorised; she was fired in 2003, and filed a whistleblower lawsuit.

Products – Consumer Healthcare In 2002, GlaxoSmithKline Consumer Healthcare introduced two GlaxoSmithKline’s principal consumer healthcare products are new prescription to over-the-counter switches: presently directed to three major areas.

Historical daily share price chart and data for GSK since 1984 adjusted for splits and dividends. The latest closing stock price for GSK as of April 10, 2025 is 33.60.

GlaxoSmithKline plc is an English public limited company.<br /> Its shares are listed on the London Stock Exchange and the<br /> New York Stock Exchange.<br /> GlaxoSmithKline plc acquired Glaxo Wellcome plc and<br /> SmithKline Beecham plc on 27th December 2000 by way<br /> of a scheme of arrangement for the merger of the two<br />

We are pleased to report that 2002 was a year of significant progress in establishing GlaxoSmithKline as one of the world’s leading pharmaceutical companies. We achieved strong financial results in 2002, despite the entry of generic competition in the USA to Augmentin, one of our major products.

Feb 14, 2002 · GlaxoSmithKline, Europe's biggest drug maker, said fourth-quarter earnings rose 16 percent on strong demand for new asthma drug Advair.

Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder.

Our archive of Annual Reports and Corporate Responsibility Reports dating back to 2000.